Cottonseed Oil for Cardiovascular Disease Risk Factors
This study is looking at how consuming cottonseed oil (CSO) intermittently affects blood fats like cholesterol and triglycerides. Researchers want to see if adding CSO to your diet a few times a week can improve these markers, especially if you're at higher risk for heart disease due to elevated cholesterol or being overweight/obese. You would receive a breakfast shake and snack three times a week for 56 days. Some participants will get shakes with CSO (at 20% or 30% of daily energy needs), while others will get a control shake without CSO. The main goal is to measure changes in your fasting and after-meal blood fat levels over 8 weeks. This study is for adults aged 25-75 with certain cholesterol levels or who are overweight/obese.
- Study design
- This is a double-blinded, randomized control trial involving 75 participants. This means neither you nor the study staff will know which intervention you are receiving, and participants are assigned to groups by chance.
- What's involved
- You would consume a provided breakfast shake and snack three times per week for 56 days. Your blood fat levels will be measured at the beginning of the study and again after 8 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your blood fat levels will be measured at the beginning of the study and after 8 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Intermittent Cottonseed Oil Consumption
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jamie Cooper, PhD · PRINCIPAL_INVESTIGATOR · University of Georgia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in fasting serum lipoprotein and cholesterol concentrationsbaseline, 8 weeks
The concentration of fasting serum total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, cholesterol/HDL ratio, and non-HDL cholesterol (mg/dL)
- Change in fasting and postprandial plasma triglyceride concentrationsbaseline, 8 weeks
The concentration of plasma triglycerides before and after the high saturated fat meal challenge at both pre-and post-intervention visits (mg/dL)
- Change in fasting and postprandial plasma non-esterified fatty acid (NEFA) concentrationsbaseline, 8 weeks
The concentration of plasma NEFAs before and after the high saturated fat meal challenge at both pre- and post-intervention visits (mEq/L)
- Change in fasting and postprandial plasma appetite control hormone concentrationsbaseline, 8 weeks
The concentration of plasma appetite control hormones before and after the high saturated fat meal challenge at both pre- and post-intervention visits. Appetite control hormones include cholecystokinin (CCK), Peptide YY (PYY), and Ghrelin (pg/mL)
- Change in fasting and postprandial subjective feelings related to appetitebaseline, 8 weeks
Visual analog scale ratings of feelings related to appetite before and after the high saturated fat meal challenge, and for the remainder of the day, at both pre- and post-intervention visits. Subjective feelings of hunger, fullness, desire to eat, prospective consumption, and a composite appetite score are measured by visual analog scales (mm).
- Change in fasting and postprandial plasma Malondialdehyde (MDA)baseline, 8 weeks
The concentration of MDA before and after the high saturated fat meal challenge at both pre- and post-intervention visits (nmol/mL).
- Change in fasting and postprandial plasma total antioxidant capacitybaseline, 8 weeks
Total antioxidant capacity before and after the high saturated fat meal challenge at both pre- and post-intervention visits (U/mL).
- Change in fasting inflammatory cytokine concentrationsbaseline, 8 weeks
The concentration of interleukin-1 beta, C-reactive protein, tumor-necrosis factor-alpha, interleukin-10, and interleukin-6 at fasting at both pre-and post-intervention visits (pg/mL).
- Change in fasting plasma markers of coagulation potentialbaseline, 8 weeks
The concentration of plasminogen activator inhibitor-1, fibrinogen, and tissue factor at fasting for both pre- and post-intervention visits (pg/mL)
- Change in fasting and postprandial plasma angiopoietin-like (ANGPTL) proteinsbaseline, 8 weeks
The concentration of ANGPTL 3, ANGPTL 4, and ANGPTL 8 before and after the high saturated fat meal challenge at both pre- and post-intervention visits (ng/mL)